Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06887010 | A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants | PHASE1 | COMPLETED | 17 | — | — | Mar 25, 2025 | Sep 16, 2025 | Oct 2, 2025 | 1 | United States |
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment
Maximum observed plasma concentration (Cmax) of ABBV-101
Tmax of ABBV-101
AUC of ABBV-101
Terminal phase elimination of half-life (t1/2) of ABBV-101
| Arm | Type | Description |
|---|---|---|
| ABBV-101: Sequence 1 | EXPERIMENTAL | Participants will receive ABBV-101 under fasting conditions in Period 1 and will receive ABBV-101 under non-fasting conditions in Period 2 |
| ABBV-101: Sequence 2 | EXPERIMENTAL | Participants will receive ABBV-101 under non-fasting conditions in Period 1 and will receive ABBV-101 under fasting conditions in Period 2. |
| Name | Type | Description |
|---|---|---|
| ABBV-101 | DRUG | Oral: Tablet |
Inclusion Criteria: * Body Mass Index (BMI) ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal at the time of screening. BMI is calculated as weight in kg divided by the square of height measured in meters. * A condition of general good health, based upon the results of a medical history...